Fig. 1 · Structure

Documents & Downloads

T0901317

Cat. No. A12652 CAS 293754-55-9

LXR/FXR agonist

T0901317 is a potent and selective agonist for LXR and FXR, with EC50s of 50 nM and 5 μM, respectively

In Stock

Publications for T0901317

3 publications citing this product

  1. Asmaa R. Abdel-Hamed, .et al. , J Med Chem Sci, 2023, 6: 250-268
  2. A O Hamouda, .et al. , Eur Rev Med Pharmacol Sci, 2022, Dec;26(23):8644-8659 PMID: 36524484
  3. Tian Yongsong, .et al. , J Labelled Comp Radiopharm, 2022, Feb;65(2):36-44 PMID: 34957593

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

T0901317 is an LXRα agonist. In recombinant assays it promoted coactivator-motif peptide recruitment (EC50 20 nM) and displaced a radiolabeled LXR ligand (IC50 20 nM). These assay endpoints are distinct from treatment concentrations. [1]

T0901317 also bound RORα and RORγ (Ki 132 and 51 nM, respectively) and suppressed their constitutive reporter activity. Its use as an LXR probe therefore requires attention to receptor selectivity. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
LXR EC50 50 nM
FXR EC50 5 μM

Cellular Effect

Cell Line Activity Value Description Reference
CHO EC50 16 nM Agonist activity at human recombinant LXRbeta expressed in CHO cells assessed as effect on secreted alkaline phosphatase by LAFbeta assay [PMID: 19853462]
CHO EC50 16 nM Agonist activity at human LXR beta receptor expressed in CHO cells by reporter assay [PMID: 17034119]
CHO-K1 EC50 0.41 μM Agonist activity at GAL4 fused LXRbeta-LBD (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay [PMID: 27283790]
CHO-K1 EC50 0.41 μM Agonist activity at Gal4-tagged LXRbeta (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay [PMID: 25677664]
CHO-K1 EC50 0.49 μM Agonist activity at GAL4 fused LXRalpha (unknown origin) transfected in CHOK1 cells after 24 hrs by luciferase reporter gene assay [PMID: 27283790]
CHO-K1 EC50 0.49 μM Agonist activity at Gal4-tagged LXRalpha (unknown origin) expressed in CHOK1 cells after 24 hrs by luciferase reporter gene assay [PMID: 25677664]
COS-7 EC50 0.011 μM Agonist activity at human LXRbeta receptor transfected in COS7 cells after 16 hrs by reporter transactivation assay [PMID: 17587573]
COS-7 EC50 0.011 μM Activation of LXRbeta co-transfected in COS7 cells with RXRalpha by reporter transactivation assay [PMID: 17416521]
CV-1 EC50 0.03 μM Agonist activity at human LXRalpha expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay [PMID: 26238323]
CV-1 EC50 0.13 μM Agonist activity at human LXRbeta expressed in African green monkey kidney CV1 cells co-expressing pTAL-LXRE including LXR response element incubated for 20 hrs by luciferase reporter gene assay [PMID: 26238323]
CV-1 EC50 140 nM Transactivation of LXRbeta (unknown origin) expressed in CV1 cells by luciferase reporter gene assay [PMID: 25435151]
CV-1 EC50 28 nM Transactivation of LXRalpha (unknown origin) expressed in CV1 cells by luciferase reporter gene assay [PMID: 25435151]
H4 EC50 0.02 μM Agonist activity at LXRbeta (unknown origin) expressed in human H4 cells co-expressing ABCA1 promoter measured after 48 hrs by cell-based transactivation assay [PMID: 27011007]
H4 IC50 4.5 μM Effect on gamma-secretase activity in human H4 cells expressing APP695 assessed as reduction of Amyloid beta-38 formation by LPECL assay [PMID: 17723298]
HEK293 IC50 > 20 μM Inverse agonist activity at human ROR-alpha1 expressed in HEK293 cells after 16 hrs by luciferase reporter gene assay [PMID: 24702856]
HEK293 EC50 0.036 μM Agonist activity at PXR (unknown origin) expressed in HEK293 cells assessed as transcriptional activity by GAL4 NR reporter cell-based assay [PMID: 24502334]
HEK293 EC50 0.066 μM Agonist activity at human LXR-beta transfected in HEK293 cells after 16 hrs by luciferase reporter gene assay [PMID: 26288691]
HEK293 EC50 0.09 μM Transactivational agonist activity at human LXRbeta transfected in HEK293 cells expressing CMX-Gal4N assessed as luciferase activity after 16 hrs by reporter gene assay [PMID: 22873709]
HEK293 EC50 0.12 μM Agonist activity at human LXR-beta expressed in HEK293 cells after 16 hrs by luciferase reporter gene assay [PMID: 24702856]

19 records · Scroll to view more

T0901317 Research Summary

This section summarizes 3 in vitro studies and 2 in vivo studies of T0901317 from 3 published references. In vitro models include recombinant LXRα ligand-binding domain; purified GST-RORα and GST-RORγ.

T0901317 In Vitro Studies

In HEK293T-derived GAL4 reporter assays, T0901317 activated LXRα (estimated EC50 0.25 μM) and inhibited RORα/γ (estimated IC50 2.0/1.7 μM) after 20 h. RORβ showed little or no activity in the receptor profile. These values describe engineered reporter systems. [2]

LXRα peptide recruitment and competitive ligand binding

Biochemical assay · Recombinant LXRα ligand-binding domain [1]

T0901317 promoted peptide recruitment and displaced radiolabeled T0314407. The functional EC50 and competition IC50 are separate assay endpoints.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LXXLL-containing peptide recruitment to LXRαEC50 20 nM[1]
Displacement of [3H]-T0314407 from LXRαIC50 20 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response testing; see Fig. 1B–C
Exposure duration
1 h for peptide sensor assay
Method
Biochemical peptide recruitment and radioligand competition
Reported limits
SPA incubation duration, vehicle and replicate counts are not specified in the retrieved assay description; peptide sensor duration is not assigned to SPA.
Methods and source locations

Compound reported in the paper: T0901317

Evidence concerns the reported experimental material; it does not validate an Adooq lot.

Results, first two paragraphs; Fig. 1A–C and caption; Materials and methods, Peptide sensor assay

LXXLL-containing peptide recruitment to LXRα: Fluorescence polarization peptide sensor assay — Results, first two paragraphs; Fig. 1A–C and caption; Materials and methods, Peptide sensor assay

Displacement of [3H]-T0314407 from LXRα: Scintillation proximity competition assay — Results, first two paragraphs; Fig. 1A–C and caption; Materials and methods, Peptide sensor assay

Direct competitive binding to RORα and RORγ

Biochemical assay · Purified GST-RORα (45 ng) and GST-RORγ (90 ng) [2]

Unlabelled T0901317 competed with 3 nM [3H]25-hydroxycholesterol for both ROR ligand-binding domains.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RORα competitive binding affinityKi 132 nM[2]
RORγ competitive binding affinityKi 51 nM[2]
Competition against 3 nM [3H]25-hydroxycholesterolEstimated IC50 RORα: 254 nM; RORγ: 81 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing concentrations of unlabelled T0901317 with 3 nM radioligand
Method
Competitive radioligand receptor binding
Reported limits
Incubation duration and vehicle are not specified in the retrieved binding description.
Methods and source locations

Compound reported in the paper: T0901317

Evidence concerns the reported experimental material; it does not validate an Adooq lot.

Materials and Methods, Reagents and Radioligand Receptor Binding Assay; Results paragraph preceding Fig. 3; Fig. 3A–D and caption

RORα competitive binding affinity: Radioligand competition — Materials and Methods, Reagents and Radioligand Receptor Binding Assay; Results paragraph preceding Fig. 3; Fig. 3A–D and caption

RORγ competitive binding affinity: Radioligand competition — Materials and Methods, Reagents and Radioligand Receptor Binding Assay; Results paragraph preceding Fig. 3; Fig. 3A–D and caption

Competition against 3 nM [3H]25-hydroxycholesterol: Radioligand competition; distinct from Ki and cellular IC50 — Materials and Methods, Reagents and Radioligand Receptor Binding Assay; Results paragraph preceding Fig. 3; Fig. 3A–D and caption

Nuclear receptor profiling and reporter concentration responses

Cell-based study · HEK293T/293T cells with GAL4 nuclear-receptor constructs and UAS-luciferase reporter [2]

T0901317 activated LXRα while suppressing constitutive RORα and RORγ reporter activity. RORβ showed little or no response in the profiling assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GAL4-LXRα reporter activationEstimated EC50 0.25 μM[2]
GAL4-RORα and GAL4-RORγ reporter repressionEstimated IC50 RORα: 2.0 μM; RORγ: 1.7 μM[2]
RORβ and GAL4-VP16 control responsesQualitative RORβ: little or no activity; GAL4-VP16: no repression reported[2]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM profiling; 0.1, 0.3, 1, 3 and 10 μM in Fig. 2
Exposure duration
20 h
Method
Cell-based GAL4/UAS reporter assays
Vehicle
DMSO
Reported limits
DMSO percentage is not specified for these reporter experiments.
Methods and source locations

Compound reported in the paper: T0901317

Evidence concerns the reported experimental material; it does not validate an Adooq lot.

Materials and Methods, GAL4 NR Library Compound Profiling; Results first paragraph; Figs. 1–2 and captions

GAL4-LXRα reporter activation: Luciferase reporter after 20 h — Materials and Methods, GAL4 NR Library Compound Profiling; Results first paragraph; Figs. 1–2 and captions

GAL4-RORα and GAL4-RORγ reporter repression: Luciferase reporter after 20 h — Materials and Methods, GAL4 NR Library Compound Profiling; Results first paragraph; Figs. 1–2 and captions

RORβ and GAL4-VP16 control responses: RORβ profile in Fig. 1; GAL4-VP16 control described in Results as data not shown — Materials and Methods, GAL4 NR Library Compound Profiling; Results first paragraph; Figs. 1–2 and captions

T0901317 In Vivo Studies

In a seven-day mouse comparison, T0901317 increased hepatic triglycerides in wild-type mice, whereas LXRα/β-null mice showed no significant hepatic increase. In a separate four-week study, 1 mg/kg daily lowered plasma triglycerides in chow-fed male C57BL/6 mice while increasing hepatic triglycerides. Plasma responses should be interpreted within each tested regimen and model. [1,3]

LXR-dependent hepatic and plasma lipid effects

Animal study · Wild-type and LXRα/β−/− mice; four groups, n=5 per group [1]

At seven days, the hepatic triglyceride and lipogenic gene responses seen in wild-type mice were markedly attenuated in LXR-null mice. Baseline lipid levels also differed by genotype.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hepatic triglycerides in wild-type mice relative to vehicleReported fold increase fivefold[1]
Hepatic triglyceride response in LXRα/β−/− miceQualitative significance No significant elevation[1]

Conditions shared by the study groups

Treatment course
7 d
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Wild-type mice receiving T0901317
50 mg/kg
Vehicle-treated wild-type miceHepatic triglycerides increased; plasma VLDL triglycerides increased; lipogenic mRNAs were induced.[1]
LXRα/β-null mice receiving T0901317
50 mg/kg
Vehicle-treated LXRα/β−/− miceNo significant hepatic triglyceride increase; little plasma lipid response and no corresponding lipogenic gene induction.[1]
Wild-type mice receiving T0901317
Model: Wild-type mice; n=5 per treatment/control group
Reported limits: Dose is on Fig. 5C–D. Route, frequency, vehicle composition, sex and age are not specified for this genotype experiment in the retrieved description.
LXRα/β-null mice receiving T0901317
Model: LXRα/β−/− mice; n=5 per treatment/control group
Reported limits: Do not import the 5 mg/kg regimen from the separate GEM microarray experiment.
Methods and source locations

Compound reported in the paper: T0901317

Evidence concerns the reported experimental material; it does not validate an Adooq lot.

Results, paragraph preceding Fig. 5; Fig. 5A–D and caption; Materials and methods, Plasma lipid analysis

Hepatic triglycerides in wild-type mice relative to vehicle: Hepatic lipid extraction and triglyceride analysis; Fig. 5C — Results, paragraph preceding Fig. 5; Fig. 5A–D and caption; Materials and methods, Plasma lipid analysis

Hepatic triglyceride response in LXRα/β−/− mice: Fig. 5C and accompanying Results — Results, paragraph preceding Fig. 5; Fig. 5A–D and caption; Materials and methods, Plasma lipid analysis

Wild-type mice receiving T0901317 · Results, paragraph preceding Fig. 5; Fig. 5A–D and caption; Materials and methods, Plasma lipid analysis

LXRα/β-null mice receiving T0901317 · Results, paragraph preceding Fig. 5; Fig. 5A–D and caption; Materials and methods, Plasma lipid analysis

Four-week lipid response in wild-type mice

Animal study · Male C57BL/6 mice, standard chow; treatment started at 8–10 weeks [3]

Longer treatment lowered circulating triglycerides while increasing liver triglycerides. Plasma IDL/LDL triglycerides and hepatic SREBP-1c/PLTP mRNA were not significantly changed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma total triglycerides versus vehicleReported percent decrease 35%[3]
Hepatic triglycerides versus vehicleQualitative significance Increased; P<0.05[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Daily
Treatment course
4 weeks
Vehicle
20% microemulsion
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
T0901317 in chow-fed male C57BL/6 mice
1 mg/kg
Vehicle microemulsion onlyPlasma total triglycerides decreased by a reported 35%, with reduced VLDL triglycerides; hepatic triglycerides increased significantly.[3]
T0901317 in chow-fed male C57BL/6 mice
Model: Male C57BL/6 mice, standard chow; treatment/control n=9 each for plasma and hepatic triglycerides
Reported limits: Vehicle components are referenced elsewhere but not detailed here; no composition reconstructed.
Methods and source locations

Compound reported in the paper: T0901317

Evidence concerns the reported experimental material; it does not validate an Adooq lot.

Methods 2.1, 2.2 and 2.7; Results 3.1; Fig. 1A–B,E–F and caption

Plasma total triglycerides versus vehicle: Commercial enzymatic lipid kits; FPLC for lipoprotein fractions — Methods 2.1, 2.2 and 2.7; Results 3.1; Fig. 1A–B,E–F and caption

Hepatic triglycerides versus vehicle: Liver lipid extraction and enzymatic assay; Fig. 1F — Methods 2.1, 2.2 and 2.7; Results 3.1; Fig. 1A–B,E–F and caption

T0901317 in chow-fed male C57BL/6 mice · Methods 2.1, 2.2 and 2.7; Results 3.1; Fig. 1A–B,E–F and caption

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 293754-55-9
Applications LXR/FXR agonist
Formula C17H12F9NO3S
Molecular Weight 481.33
SMILES
C1=CC=C(C=C1)S(=O)(=O)N(CC(F)(F)F)C2=CC=C(C=C2)C(C(F)(F)F)(C(F)(F)F)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL (182.82 mM)
Water Insoluble
Ethanol 88 mg/mL (182.82 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
5 mg/mL
Vehicle
2% DMSO+35% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

T0901317 Research References

  1. [1] Joshua R Schultz, Hua Tu, Alvin Luk, et al. Role of LXRs in control of lipogenesis Genes & development (2000). PMID: 11090131 DOI: 10.1101/gad.850400 Source material
  2. [2] Naresh Kumar, Laura A Solt, Juliana J Conkright, et al. The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-α/γ Inverse Agonist Molecular pharmacology (2010). PMID: 19887649 DOI: 10.1124/mol.109.060905 Source material
  3. [3] Dacheng Peng, Richard A Hiipakka, Jing-Tian Xie, et al. Differential Effects of Activation of Liver X Receptor on Plasma Lipid Homeostasis in Wild Type and Lipoprotein Clearance-Deficient Mice Atherosclerosis (2010). PMID: 19632679 DOI: 10.1016/j.atherosclerosis.2009.07.016 Source material

Publications

3 publications citing this product

  1. Asmaa R. Abdel-Hamed, .et al. , J Med Chem Sci, 2023, 6: 250-268
  2. A O Hamouda, .et al. , Eur Rev Med Pharmacol Sci, 2022, Dec;26(23):8644-8659 PMID: 36524484
  3. Tian Yongsong, .et al. , J Labelled Comp Radiopharm, 2022, Feb;65(2):36-44 PMID: 34957593

Added to your cart

View Cart Checkout
Loading...